Cytokinetics Inc
CYTK
ISIN null / Valor 21533074
Cytokinetics Inc
UMushroom community rating:
About company
Cytokinetics Inc. is a biopharmaceutical company with a specialized focus on the development of innovative therapies aimed at enhancing muscle function for individuals suffering from debilitating diseases where muscle performance is compromised. Established over 25 years ago in South San Francisco, California, the company has carved a niche in muscle biology, pioneering the discovery, development, and commercialization of muscle activators and inhibitors. These novel therapeutic agents are designed as potential treatments for a range of serious conditions affecting muscle health. Under the leadership of experienced industry professionals, Cytokinetics has made significant strides in scientific research, evidenced by its extensive portfolio of over 115 scientific publications, participation in more than 100 clinical trials, and the securing of numerous patents. The company's commitment to advancing muscle biology research extends to its active engagement with the healthcare and scientific communities through peer-reviewed journals and medical forums, aiming to contribute meaningfully to patient care and medical knowledge.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (18.11.2025):
Cytokinetics Inc reported its financial and clinical results for the third quarter of 2025, showcasing a strengthened balance sheet, increased revenues, and continued progress in its clinical development programs. The update highlighted robust cash reserves, strategic financing activities, and significant advancements in the regulatory and commercial preparations for its key product candidate, aficamten.
Strong Cash Position and Strategic Financing
As of September 30, 2025, Cytokinetics Inc had approximately $1.25 billion in cash, cash equivalents, and investments—up from $1.04 billion in June 2025. The company bolstered its financial strength by issuing $750 million aggregate principal amount of its Convertible Senior Notes, netting $729.5 million in proceeds, and received an additional $100 million from a Royalty Pharma term loan tranche.
Revenue Growth and Increased R&D Investment
For Q3 2025, Cytokinetics Inc reported total revenues of $1.9 million, a notable increase from $0.5 million in the same quarter of 2024. Research and development expenses also rose to $99.2 million, partly due to heightened clinical trial activities and increased personnel costs, including non-cash stock-based compensation.
Clinical and Regulatory Progress
The company continued to advance its cardiac muscle programs, particularly for aficamten. Key updates included robust FDA interactions regarding the NDA review, active regulatory discussions in China and the EU, and positive clinical trial results from MAPLE-HCM. These developments reinforce the potential of aficamten as it moves closer to its PDUFA target date of December 26, 2025 and enhance preparations for a U.S. commercial launch.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
7668 M
Market cap (USD)
1,313,652
Daily traded volume (Shares)
47.775 / 46.6
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Joaquim Silva
Duarte *****
Duarte *****
EQUITIES OF THE SAME SECTOR
